Bristol-Myers Squibb announced in a quarterly filing with the Securities and Exchange Commission this week that the Department of Justice has ended its investigation into allegations that the pharmaceutical giant violated the Foreign Corrupt Practices Act.

Learn More
Already a member? Sign in to an existing account.

Jaclyn Jaeger is a freelance contributor to Compliance Week after working for the company for 15 years. She writes on a wide variety of topics, including ethics and compliance, risk management, legal,...